Search the Newsreel

What Adecoagro (AGRO)'s Record Fertilizer and Ethanol-Driven EBITDA Surge Means For Shareholders

Adecoagro (AGRO) recently reported record second-quarter and first-half 2026 results, driven by strong fertilizer and ethanol performance, which led to a significant EBITDA surge. This performance, especially from sharply higher urea production and ethanol maximization, supports the company's ability to convert volatile commodity cycles …

HC Wainwright Cuts Earnings Estimates for Hemab Therapeutics

HC Wainwright has lowered its FY2026 earnings per share estimate for Hemab Therapeutics to a loss of $3.19 per share, down from $3.12, while reaffirming a "Buy" rating and a $60 price target. The revision follows Hemab's recent quarterly EPS of $(0.80), which missed …

Will Record EBITDA and Earnings Turnaround Reshape Adecoagro's (AGRO) Risk‑Reward Narrative?

Adecoagro (AGRO) reported strong Q2 2026 results, including US$531.01 million in sales and US$18.21 million in net income, reversing previous losses and achieving record adjusted EBITDA. This performance, along with a US$35.0 million dividend approval, suggests improving profitability and balance sheet repair. However, the …

Adecoagro Q2 Earnings Call Highlights

Hemab Therapeutics (NASDAQ:COAG) Hits New 52-Week High After Analyst Upgrade

Hemab Therapeutics (NASDAQ:COAG) shares recently hit a new 52-week high of $54.19 following an analyst upgrade from HC Wainwright, which raised its price target to $60 and maintained a Buy rating. The company holds a "Moderate Buy" consensus from analysts with an average price …

Adecoagro SA earnings missed by $0.64, revenue fell short of estimates

Adecoagro SA (NYSE: AGRO) reported second-quarter EPS of $0.13, significantly missing analyst estimates of $0.76 by $0.63. The company's revenue also fell short at $531.01 million against an estimated $702.6 million. Despite the earnings miss, Adecoagro SA's stock has seen positive EPS revisions recently, …

Adecoagro S.A. 2026 Q2 - Results - Earnings Call Presentation (NYSE:AGRO) 2026-08-12

Hemab Therapeutics (COAG): Capital International Investors discloses 7.7% ownership

Capital International Investors has disclosed a 7.7% beneficial ownership stake in Hemab Therapeutics Holdings, Inc. (COAG), as per a Schedule 13G filing. The firm beneficially owns 3,603,876 shares of common stock, representing 7.7% of the 46,705,410 shares outstanding, and holds sole voting and dispositive …

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Average Recommendation of "Moderate Buy" by Analysts

Analysts have issued a "Moderate Buy" consensus recommendation for Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG), with an average 12-month price target of $49.60. The company recently reported a quarterly loss per share of $0.80, missing consensus estimates, but insiders have been actively purchasing shares. Hemab …

Form 8K Hemab Therapeutics Holdings For: 11 August By Investing.com

This article from Investing.com announces the filing of a Form 8K by Hemab Therapeutics Holdings for August 11. The brief piece includes the stock market category but provides no further details on the content of the Form 8K.

Adecoagro S.A. Stock 12‑Month Price Target Cut to $13.42, Implies 43% Upside

Adecoagro S.A.'s average 12-month price target has been lowered by analysts from $13.58 to $13.42, suggesting a potential upside of 43% from its Aug. 11 closing price. The consensus rating for AGRO stock remains "Hold" among 7 analysts, with one "Buy," five "Holds," and …

H.C. Wainwright Maintains Hemab Therapeutics Holdings(COAG.US) With Buy Rating, Raises Target Price to $60

H.C. Wainwright has reaffirmed its Buy rating on Hemab Therapeutics Holdings (COAG.US) and increased its target price to $60. This indicates a positive outlook from the firm regarding the company's future performance and stock valuation.

Adecoagro (NYSE:AGRO) Releases Quarterly Earnings Results

Adecoagro: Q2 Earnings Snapshot

Adecoagro S A : Q2 Financial Statements

Adecoagro S.A. has released its condensed consolidated interim financial statements for the second quarter and six months ended June 30, 2026. The report details the company's financial performance, including a profit of $69.058 million for the six-month period, significantly up from $1.664 million in …

Hemab Therapeutics (COAG) widens loss but builds $457.5M cash war chest

Hemab Therapeutics (NASDAQ:COAG) Price Target Raised to $60.00 at HC Wainwright

HC Wainwright has increased its price target for Hemab Therapeutics (NASDAQ:COAG) to $60.00 from $52.00, maintaining a "buy" rating, which suggests a potential upside of 16.91%. The company has a consensus "Moderate Buy" rating from analysts, with shares recently trading up 2.9% despite missing …

Earnings Flash (COAG) Hemab Therapeutics Posts Q2 Net Loss $0.80 a Share, vs. FactSet Est of $0.56 Loss

Hemab Therapeutics (COAG) reported a Q2 net loss of $0.80 per share, which is wider than the FactSet estimate of a $0.56 loss. The company is a clinical-stage biotechnology firm focused on developing therapies for blood coagulation disorders, with lead assets in Phase 1/2 …

Hemab Therapeutics reports Q2 2026 net loss of $24.2M, cash runway into 2029 after $317M IPO proceeds

Hemab Therapeutics reported a Q2 2026 net loss of $24.2 million but maintains a strong cash position of $457.5 million, expected to fund operations into 2029 following $317.2 million from its IPO. The company reiterated key clinical milestones for sutacimig, HMB-002, and the newly …

Hemab Therapeutics Holdings (Nasdaq:COAG) - analisi del titolo

Hemab Therapeutics Holdings, Inc. (Nasdaq:COAG) is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders in the US and Denmark. The company's pipeline includes sutacimig (HMB-001) for Glanzmann thrombasthenia and Factor VII deficiency, HMB-002 for Von Willebrand Disease, and the newly …

ETFs Investing in Adecoagro S.A. Stocks

This article lists several ETFs that invest in Adecoagro S.A. stocks, detailing their market value, weight, issuer, management style, focus, expense ratio, AUM, price, and historical returns. The ETFs cover various investment strategies including total market, consumer staples, natural resources, agriculture, bioenergy, and small-cap …

Understanding Momentum Shifts in (AGRO)

This article from Stock Traders Daily analyzes Adecoagro S.a. (AGRO), identifying weak near and mid-term sentiment that could challenge its long-term positive outlook. It provides key support and resistance levels, outlines three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hedging), and details signal …

Hemab Therapeutics (NASDAQ: COAG) investors detail 5.1% passive ownership stake

A group of related investment entities, led by Invus Public Equities and Avicenna Life Sci Master Fund, has reported a passive ownership stake in Hemab Therapeutics Holdings, Inc. Raymond Debbane is deemed to beneficially own 5.1% of Hemab Therapeutics' common stock, corresponding to 2,366,235 …

Adecoagro S.A. (NYSE:AGRO) Given Average Rating of "Reduce" by Analysts

Adecoagro S.A. (NYSE:AGRO) has received a consensus "Reduce" rating from analysts, with an average 12-month price target of $12.12. Recent analyst coverage has become more cautious, including downgrades from JPMorgan, Weiss Ratings, and Citigroup. The company's shares opened at $9.45, below key moving averages, …

Adecoagro S.A. Stock 12‑Month Price Target Cut to $13.58, Implies 46% Upside

Adecoagro S.A.'s (AGRO) average 12-month price target has been reduced from $13.68 to $13.58 by 7 analysts, with individual forecasts ranging from $10.5 to $16. This updated target suggests a potential upside of approximately 46% from the August 5 closing price. The consensus rating …

Biotech Stocks At 52-Week Highs - DCTH +22% On Q2 Results, ANRO, COAG, MNPR, NRIX

(RTTNews) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation. Delcath Systems Inc. (DCTH) Delcath Systems is an interventional oncology company focused on developing therapies for primary and …

FMR LLC reports 7.9% Hemab Therapeutics (COAG) stake on Schedule 13G

FMR LLC has reported a 7.9% beneficial ownership stake in Hemab Therapeutics Holdings Inc (COAG), totaling 3,697,837 shares of common stock, as detailed in a Schedule 13G filing. The investment firm holds sole voting and sole dispositive power over these shares, with Abigail P. …

Sofinnova group (NASDAQ: COAG) discloses 5.4% Hemab Therapeutics ownership on Schedule 13G

Sofinnova Crossover II SLP, along with Sofinnova Partners SAS and its investment committee members, has reported a beneficial ownership of 2,511,212 shares of Hemab Therapeutics Holdings, Inc. common stock. This constitutes a 5.4% stake in the company, based on 46,705,410 shares outstanding as of …

Adecoagro (AGRO) Expected to Announce Earnings on Thursday

Adecoagro (AGRO) is projected to announce its Q2 2026 earnings before market open on Thursday, August 13th, with analysts anticipating $0.544 per share in earnings and $602.0 million in revenue. The earnings call is scheduled for August 14th at 8:00 AM ET. The company …

Hemab Therapeutics Holdings Ord Shs (Proposed)

Adecoagro SA Shs Cert Deposito Arg Repr 1 Sh Revenue Breakdown – BCBA:ADGOC

This article provides a revenue breakdown for Adecoagro SA Shs Cert Deposito Arg Repr 1 Sh (ADGOC). It highlights that Brazil was the primary contributor to the company's revenue, generating $442.90 million USD in the last year, an increase from $387.01 million USD in …

Hemab Therapeutics (NASDAQ:COAG) Trading Down 4.8% - What's Next?

Adecoagro (NYSE:AGRO) Stock Price Down 4.6% - Here's Why